DREAMM

Belantamab mafodotin: mechanism of action

Belantamab mafodotin

About Multiple Myeloma

MM is characterized by the uncontrolled growth of malignant plasma cells. All MM cells express BCMA. The incidence of MM is increasing despite improved outcomes with currently available therapies. The clinical course typically results in disease recurrence with progressively shorter disease-free intervals, highlighting the need for novel, effective, targeted agents.13,15-17

Belantamab Mafodotin

What is BCMA?

BCMA is a membrane protein that supports myeloma cell proliferation and survival. Belantamab mafodotin specifically binds to BCMA and eliminates myeloma cells by a multimodal mechanism including delivering mafodotin to BCMA-expressing malignant cells, enhancing ADCC/ADCP, and by potentiating immunogenic cell death.12-14

Belantamab Mafodotin

ADCC/ADCP, antibody-dependent cellular cytotoxicity/antibody-dependent cellular phagocytosis; BCMA, B-cell maturation antigen; MM, multiple myeloma

DREAMM

SE-GBL-BLM-WCNT-200008 June 2022

This information is intended for healthcare providers only. This website includes ongoing clinical trials for both approved and investigational compounds. Some agents are approved in select indications. Inclusion in this website does not imply regulatory approval for these compounds or all indications. Information about all trials can be found at www.clinicaltrials.gov. All clinical study information updated as of May 2021.

GSK

© 2001-2022 GlaxoSmithKline plc. All rights reserved. Trade marks are owned by or licensed to the GSK group of companies.

GlaxoSmithKline plc. Registered in England and Wales No. 3888792.

Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.